Radiotherapy
Clinical pearls for primary care
Genevieve Chaput MD MA CCFP(PC) Laura Regnier MSc MD CCFP

Family physicians play an integral role in the management of their patients with cancer. At least 50% of cancer patients will undergo radiation therapy at some point during their illness trajectory. This article summarizes the basic principles, techniques, indications, and side effects (SEs) of radiotherapy.

Ionizing radiation causes damage to DNA and other critical machinery of rapidly dividing cells, resulting in cell death and tumour shrinkage. The unit of measurement for radiation is the gray (Gy), which is equal to 1 joule of absorbed energy per kilogram of tissue. The total planned radiation dose is divided into multiple sessions, referred to as fractions, to optimize malignant cell damage while minimizing toxicity to normal tissues and organs.

Treatment techniques
Radiotherapy can be delivered using an external source (external beam radiotherapy [EBRT]), an internal source (brachytherapy), or by intravenous administration of radioisotopes that are selectively absorbed by the targeted tissue. The most common form of radiotherapy is EBRT, which is delivered by a linear accelerator. These machines use sophisticated software systems to direct x-rays (photons) or electrons to a target. The first step in preparing for EBRT is a simulation session. This process involves imaging, usually computed tomography or magnetic resonance imaging; applying markings or tattoos to assist in landmarking the patient’s position; and immobilization with various devices (thermoplastic shells, wedges, bite blocks) on the treatment table. The radiation oncologist and physicist then create a treatment plan that will specify the volume of tissue to be treated, the dose to be delivered, and the number of fractions required to safely deliver this dose.

To maximize the dose to the target and minimize exposure of normal tissue, radiation beams are delivered from several directions to match the target volume as closely as possible in a process known as conformal radiotherapy. Image-guided and intensity-modulated radiotherapy use 3-dimensional imaging to allow multiple regions within the target to be treated simultaneously with different dose intensities. Machines with these capabilities can perform stereotactic body radiotherapy and stereotactic radiosurgery, in which high-intensity radiation is delivered in just a few fractions. A linear accelerator mounted on a robotic arm (CyberKnife; Accuray Inc) has the added function of motion tracking using real-time imaging to adjust for breathing and other involuntary movements during treatment to sites such as the brain, spine, thorax, abdomen, and prostate, where the risk of damage to adjacent tissue is high.

External beam radiotherapy treatments are usually split into daily fractions that are given Monday to Friday, or occasionally twice daily or once weekly. The treatment itself takes minutes to deliver but the whole process, including positioning, takes 15 to 30 minutes. A typical curative regimen delivers a total dose ranging from 40 to 80 Gy given over 3 to 8 weeks. Hypofractionation trials have demonstrated that the total dose can be safely given in fewer fractions while achieving similar response rates. This has improved resource use and has been pivotal in decreasing the frequency of visits to cancer centres during the coronavirus disease 2019 pandemic. For example, the treatment of prostate cancer can be decreased from 7 or 8 weeks to 4 weeks, and breast cancer treatment can be reduced from 5 weeks to 3 weeks.

Indications
Curative radiotherapy (given as monotherapy or concurrently with chemotherapy in the neoadjuvant or adjuvant setting) has a high risk of SEs and complications, and so the patient’s overall health and comorbidities must be carefully considered and balanced with the chance of cure. Conversely, palliative radiation is intended to provide rapid symptom relief, and late toxicity is less of a concern. For this reason, larger doses are often given as a single fraction or over a few days rather than weeks (Table 1).

Family physicians should be aware of the indications for palliative radiation therapy, as it is an effective tool in the provision of palliative care (Table 2). The therapeutic effects of radiation are not immediate and the time to response varies from 1 to 4 weeks; patients being considered for palliative radiation should have a life expectancy of at least 1 month. Most cancer centres have rapid palliative radiation referral programs that facilitate access to treatment, with wait times of only 2 to 3 days, and same-day assessment and treatment.

Treatment-related SEs and their management
Although technical advancements have contributed to reducing radiotherapy-related toxicity, many patients remain afflicted with taxing SEs. Side effects are classified as early or late, the former presenting during or within weeks of radiotherapy completion, and the latter manifesting months to years thereafter.

Side effects can be psychological or physical in nature. Psychological SEs include distress, anxiety, and...
Table 1. Typical curative vs palliative radiotherapy dosing regimens: Many different treatment schedules exist, and regimens vary depending on the neoadjuvant vs adjuvant setting; use of radiation alone vs radiation and chemotherapy; tumour stage, size, and location; and technique employed.

| MALIGNANCY                          | CURATIVE TREATMENT DOSE       | PALLIATIVE DOSE                          |
|------------------------------------|-------------------------------|-----------------------------------------|
| GBM                                | 60 Gy/30 fractions, 40 Gy/15 fractions* | 25 Gy/5 fractions                       |
| Brain metastasis (whole brain radiation) | NA                           | 20 Gy/5 fractions, 30 Gy/10 fractions   |
| SCLC (prophylactic cranial irradiation) | 25 Gy/10 fractions            | NA                                      |
| Brain metastasis (SRS)             | NA                           | 15-24 Gy/1-3 fractions                  |
| Head and neck                      | 70 Gy/35 fractions            | 30 Gy/10 fractions, 8 Gy/1 fraction     |
| Lung, stage I to II (SBRT)         | 54-60 Gy/3-8 fractions        | NA                                      |
| Lung, stage III                    | 60 Gy/30 fractions            | 30 Gy/10 fractions                      |
| Esophagus                           | 50 Gy/25 fractions            | 30 Gy/10 fractions                      |
| Breast                              | 50 Gy/25 fractions, 40 Gy/15 fractions | NA                                      |
| Prostate                            | 70 Gy/35 fractions, 60 Gy/20 fractions | NA                                      |
| Rectum                              | 45 Gy/25 fractions, 50 Gy/30 fractions | 25 Gy/5 fractions                      |
| Bone metastasis                     | NA                           | 800 cGy/1 fraction or 20 Gy/5 fractions |
| Spinal cord compression             | NA                           | 800 cGy/1 fraction or 20 Gy/5 fractions |
| SVCO                                | NA                           | 20 Gy/5 fractions                       |

*Radical treatment for GBM (treatment for GBM is not curative).
NA—not applicable, GBM—glioblastoma multiforme, SBRT—stereotactic body radiotherapy, SCLC—small cell lung cancer, SRS—stereotactic radiosurgery, SVCO—superior vena cava obstruction.
Data from Gunderson and Tepper.

Table 2. Palliative indications for radiation oncology referral

| INDICATIONS                                      | PATIENTS WITH RESPONSE TO TREATMENT                  |
|--------------------------------------------------|------------------------------------------------------|
| Pain from bone metastases                        | 60%-88% partial relief, 17%-24% complete relief      |
| Spinal cord compression symptoms                  |                                                      |
| • Weakness or loss of motor function              | 60%                                                  |
| • Pain or reducing analgesic use                  | 61.9%                                                |
| Hemoptysis                                        | 86%                                                  |
| Gastric bleeding                                  | 69%                                                  |
| Hematuria                                         | 57%-72%                                              |
| Vaginal bleeding                                  | 100%                                                 |
| Rectal bleeding                                   | 89%                                                  |
| Overall primary bleeding control rate             | 89%                                                  |
| Dyspnea or airway obstruction, cough              | 66%, 71%                                             |
| Superior vena cava obstruction                    | 83%-86%                                             |
| Obstruction                                       |                                                      |
| • Dysphagia, or gastric outlet, biliary, or rectal obstruction | 35%-45%                                             |
| Brain metastases                                  |                                                      |
| • Physical condition                              | 37%                                                  |
| • Global health status                            | 82%                                                  |

depression, and must not be overlooked. Distress screening using the Edmonton Symptom Assessment System–Revised, distress thermometer, or Patient Health Questionnaire–2, and prompt care and referrals for psychosocial issues are key components of management. Moreover, family physicians should rule out potentially contributing causes, including radiotherapy-induced hypothyroidism and vitamin B12 malabsorption.

Physical SEs include cancer-related fatigue; skin SEs; head and neck SEs; and cardiac, pulmonary, gastrointestinal, or sexuality-related SEs (Table 3). Cancer-related fatigue affects nearly 80% of patients who receive chemotherapy and-or radiotherapy; the mainstay of management is nonpharmacologic, with patient support, physical exercise, yoga, acupuncture, cognitive-behavioural therapy, and other mindfulness-based therapies. In refractory cases, methylphenidate might be considered; modafinil is not recommended. Moreover, potential contributing factors, such as anemia and cardiac or endocrine abnormalities, should be readily managed.

Radiation dermatitis is a common skin radiation-related SE observed in the head and neck, breast, vulva, and anorectal areas owing to the proximity to the skin surface. The severity of the reaction is dose dependent. Loose clothing and avoidance of perfumes or harsh soaps are recommended general measures to aid in skin preservation. Protective spray-on barrier films might be useful in delaying the onset and minimizing the
severity of skin reactions.\textsuperscript{29} Skin irritation associated with erythema and dry desquamation is managed with weak topical steroids (1% hydrocortisone) and moisturizers (glaxal base), whereas moist desquamation often requires the use of antibacterial creams such as silver sulfadiazine or bacitracin–polymyxin B.\textsuperscript{30,31} In the anogenital area, saline or aluminum acetate solution soaks and sitz baths are recommended.

Head and neck radiotherapy SEs include oral mucositis, taste alterations, xerostomia, hypothyroidism, dysphagia, and lymphedema. Cancer Care Ontario and BC Cancer provide easy-to-use clinical guidelines on how to address these frequent SEs (Box 1).\textsuperscript{32–36} Radiation to the head and neck can also lead to carotid artery stenosis, thereby increasing cerebrovascular disease risk. Family physicians therefore have a crucial role in screening for

| Table 3. Radiotherapy side effects |
|-----------------------------------|
| **LOCATION** | **ACUTE** | **SUBACUTE** | **LATE** |
| General | • Fatigue | | • Second malignancy in the field of radiation (< 1% risk in older adults; higher risk in pediatric or younger populations) |
| Skin | • Sunburned appearance (erythema, pruritus) • Dry skin peeling (or dry desquamation) • Weeping skin (or wet desquamation) • Ulceration and bleeding (rare) | • Radiation pneumonitis (syndrome of cough, dyspnea, hypoxia, fever, radiologic changes) | |
| Lung | • Cough | | • Reduced pulmonary function |
| Heart | • No specific acute or subacute effects | | • Coronary artery disease • Pericarditis |
| Head and neck | • Mucositis • Xerostomia (dry mouth) • Dysphagia • Odynophagia • Weight loss (from poor nutritional intake) | | • Dysphagia or odynophagia • Dysgeusia (changes in taste) • Voice changes • Dental complications • Osteonecrosis of the mandible (rare) |
| Esophagus | • Esophagitis • Nausea • Anorexia | | • Esophageal perforation (rare) • Tracheoesophageal fistula (rare) • Esophageal stricture (rare) |
| Small and large bowel | • Nausea and vomiting | | • Radiation colitis (rare) |
| Anorectal | | • Radiation proctitis (rare) | • Chronic bowel habit change • Rectal urgency • Fistulae, strictures, obstructions (rare) |
| Bladder and prostate | • Irritative or obstructive urinary symptoms • Sexual dysfunction • Radiation cystitis (rare) • Urethra stricture (rare) | | |
| Vagina | • Vaginitis (irritation) | | • Vaginal stenosis • Fistula (rare) |
| Ovary | • No specific acute or subacute effects | | • Induced menopause • Infertility |
| Brain | • Increased ICP • Headache • Seizures • Nausea and vomiting | • Fatigue • Cognitive decline • Cataracts (lens effects) • Hearing loss (cochlear effects) • Hormonal imbalance (pituitary or hypothalamic effects) | |
| Bone | • Marrow suppression • Pain flares | | • Fracture due to osteopenia • Bone growth arrest (pediatric) |

ICP—intracranial pressure. Adapted from Ingledew et al.\textsuperscript{27}
Box 1. Radiotherapy side effect resources

| Head and neck side effects |
|-----------------------------|
| • Cancer Care Ontario: [https://www.cancercareontario.ca/en/symptom-management/3156](https://www.cancercareontario.ca/en/symptom-management/3156) |
| • BC Cancer: [http://www.bccancer.bc.ca/patient-and-public-info-site/Documents/RT%20Side%20Effects%20Education%20Materials/Care-of-Radiation-Therapy-Side-Effects-Head-and-Neck.pdf](http://www.bccancer.bc.ca/patient-and-public-info-site/Documents/RT%20Side%20Effects%20Education%20Materials/Care-of-Radiation-Therapy-Side-Effects-Head-and-Neck.pdf) |

Cancer-related lymphedema:
- [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7755442/pdf/conc-27-336.pdf](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7755442/pdf/conc-27-336.pdf)

Radio-induced lung injury:
- [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8097634/pdf/main.pdf](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8097634/pdf/main.pdf)

Pelvic radiation disease:
- [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7253739/table/tbl1-conc-27-107/?report=objectonly](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7253739/table/tbl1-conc-27-107/?report=objectonly)

Overview of common radiotherapy side effects and their management:
- [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7253739/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7253739/)

and managing comorbid conditions including smoking, diabetes, dyslipidemia, and coronary and peripheral artery diseases.37

Thoracic radiotherapy can cause radiation-induced lung injury and radiation-induced heart disease. Radiation-induced lung injury can present as dyspnea and lead to lung fibrosis, adversely affecting quality of life.38 Radiation-induced lung injury comprises an acute inflammatory phase and a chronic fibrotic phase, the former referred to as radiation pneumonitis (occurs within 3 months after radiotherapy) and the latter known as radiation fibrosis.39 Clinical presentation often features dyspnea, dry cough, and occasionally fever, but physical examination findings are typically unremarkable.39 Family physicians must consider radiation-induced lung injury in their differential diagnosis. Symptomatic patients can be treated with steroids.39 Radiation-induced heart disease can occur years after radiotherapy and presents as pericardial disease, cardiomyopathy, valvular disease, coronary artery disease, or conduction anomalies.40 Primary and secondary prevention measures are the cornerstone of care and include screening for and management of cardiovascular disease risk factors (diabetes, hypertension, obesity, dyslipidemia, smoking).41 A baseline echocardiogram 6 to 12 months after radiotherapy and referral to a cardiologist might also be indicated.41

Pelvic cancers are treated with radiotherapy more than any other cancer site, and can result in gastrointestinal toxicity, sexual issues, and fertility concerns. Pelvic radiation disease (PRD) refers to mild to severe temporary or long-term gastrointestinal symptoms that can substantially impact quality of life.42 Given frequent non–PRD-specific gastrointestinal symptoms including urgency, diarrhea, and rectal bleeding can occur, systematic investigation is recommended.43 Of note, succralfate, aminosalicylates, corticosteroid enemas, bile acid sequestrants, selenium, fomotidine, and dietary modifications have less evidence for potential benefit in PRD management.44 Vaginal dryness and stenosis, decreased libido, dyspareunia, and erectile dysfunction can arise owing to pelvic radiation and can negatively impact intimacy and self-esteem.45 Nonhormonal lubricants may help with vaginal dryness experienced during intercourse.46 Vaginal dilators and pelvic physiotherapy might improve vaginal elasticity.45 Erectile dysfunction can be treated with phosphodiesterase 5 inhibitors.46 Intimacy and self-esteem issues can also result from radiotherapy-induced bladder or bowel dysfunction.46 Family physicians should screen for intimacy and sexual concerns and refer patients to a psychologist or sex therapist when warranted.46 Finally, as pelvic radiotherapy might increase the risk of preterm labour, spontaneous miscarriages, low birth weight, and placental anomalies, close pregnancy monitoring by a multidisciplinary team is indicated.47 Key resources for management of common radiotherapy SEs are presented in Box 1.32–36

Conclusion
Radiotherapy is widely used for the curative and palliative treatment of malignancies. Family physicians are well suited to screen for and address radiotherapy-related SEs and complications, manage underlying comorbid conditions, and promote healthy lifestyle habits in cancer survivors.

Dr Genevieve Chaput is Assistant Professor at McGill University in Montreal, Que, an attending physician in the departments of family medicine and secondary care and oncology at the McGill University Health Centre, and Medical Director of the Vaudreuil-Soulanges Palliative Care Residence. Dr Laura Regnier is Assistant Professor in the Department of Family Medicine at the University of Ottawa in Ontario, and a general practitioner in oncology in the Radiation Oncology Department at The Ottawa Hospital Cancer Centre.

Competing interests
None declared

References
1. Delaney G, Jacob S, Featherstone C, Barton M. The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer 2005;105(6):1192-37. Erratum in: Cancer 2006;109(3):466.
2. Gunderson LL, Tepper JE, editors. Clinical radiation oncology. 5th ed. Philadelphia, PA: Elsevier; 2021.
3. Baskar R, Lai KY, Yeo B, Yosh MM. Radiation and cancer therapy: current advances and future directions. Int Med Sci 2012;9(3):193-9. Epub 2012 Feb 27.
4. Goyal S, Kataria T. Image guidance in radiation therapy: techniques and applications. Radiol Res Pract 2014;2014:105604. Epub 2014 Dec 17.
5. Taylor A, Powell MEB. Intensity-modulated radiotherapy—what is it? Int J Cancer Imaging 2004;20(4):68-73.
6. Kilby W, Dooley JR, Kuduvalli G, Sayer S, Maurer CR Jr. The CyberKnife robotic radiosurgery system in 2010. Technol Cancer Res Treat 2010;9(3):433-52.
7. Lutz ST, Chow EL, Harttell WF, Konski AA. A review of hypofractionated palliative radiotherapy. Cancer 2010;116(6):1542-70.
8. Rathod S, Dubey A, Bashir B, Sivananthan G, Leylikli A, Chowdhury A, et al. Bracing for impact with the new 4R’s in the COVID-19 pandemic—a provincial thoracic radiation oncology consensus. Radiother Oncol 2020;149(4):1-7. Epub 2020 Apr 8.
9. Guo W, Sun YC, Bi JQ, He P, Xiao L. Hypofractionated radiotherapy versus conventional radiotherapy in patients with intermediate- to high-risk localized prostate cancer: a meta-analysis of randomized controlled trials. BMC Cancer 2019;19(1):1063.
10. Koulis TA, Pan T, Olivotto IA. Hypofractionated whole breast radiotherapy: current perspectives. Breast Cancer (Dove Med Press) 2017;2:363-70.
11. Lutz S, Balboni T, Jones L, Lo S, Pettit J, Rich SE, et al. Palliative radiation therapy for bone metastases: update of an ASTRO Evidence-Based Guideline. Pract Radiat Oncol 2017;7(1):e4-12. Epub 2016 Aug 5.
12. Rades D, Cacciole J, Conde-Moreno AJ, Segedin B, But-Haddizic J, Grosselj B, et al. Precision radiation therapy for metastatic soft tissue cord compression: final results of the PRE-MODE trial. Int J Radiat Oncol Biol Phys 2020;106(4):380-9. Epub 2019 Dec 5.

13. Fleming C, Rimmer A, Foster A, Woe KM, Zhang Z, Wu AJ. Palliative efficacy and local control of conventional radiotherapy for lung metastases. Ann Palliat Med 2017;6(4):521-7. Epub 2017 Mar 21.

14. Lee YM, Lee JK, Iang HS. Palliative external beam radiotherapy for the treatment of tumor bleeding in inoperable advanced gastric cancer. BMC Cancer 2017;17(1):541. Ertatum in: BMC Cancer 2018;18(1):232.

15. Oggia M, Kawamoto J, Yamashita K. Palliative radiotherapy for gross hematuria in patients with advanced cancer. Sci Rep 2021;11(1):9333.

16. Sapienza LS, Ning MS, Jhingran A, Lin LL, Leão CR, da Silva BB, et al. Short-course palliative radiation therapy leads to excellent bleeding control: a single centre-retrospective study. Clin Transl Radiat Oncol 2018;4:40-6.

17. Ample F, Caidtò G, Prigioni C. Palliative radiotherapy for superior vena cava obstruction by lung cancer: a major issue about timing and a minor issue about efficacy. Ann Thorac Med 2012;7(3):170-1.

18. Pennement MG, De Iorio PB, Harvey JA, Stephens S, Au HY, O’Callaghan CJ, et al. Palliative chemoradiotherapy versus radiotherapy alone for dysphagia in advanced oesophageal cancer: a multicentre randomised controlled trial (TRGOS 03.01). Lancet Gastroenterol Hepatol 2016;1(2):w1-w4. Epub 2017 Dec 14.

19. Sutek P, Feistek Z, Todor N, Nagy V. Survival and quality of life after whole brain radiotherapy with 3D conformal boost in the treatment of brain metastases. Med Parm Ph 2019;39(1):43-51. Epub 2019 Jan 15.

20. Kain W, Bennett Y, Yi M, Robinson B, James M. 30-Day mortality following palliative radiotherapy. J Med Imaging Radiat Oncol 2020;64(4):570-9. Epub 2020 Jun 27.

21. Park KR, Lee CG, Tseng YD, Liao JJ, Reddy S, Bruera E, et al. Palliative radiation therapy in the last 30 days of life: a systematic review. Radiolther Oncol 2017;125(2):199-9. Epub 2017 Oct 16.

22. Denny KE, Harris G, Kamel R, Barnes T, Balboni T, Fenton P, et al. Rapid access palliative radiotherapy programmes. Clin Oncol (R Coll Radiol) 2020;32(10):704-12. Epub 2020 Aug 18.

23. Citrin DE. Recent developments in radiotherapy. N Engl J Med 2017;377(2):2200-1.

24. Bentzen SM. Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology. Nat Rev Cancer 2006;6(9):702-13.

25. Howell D, Keshavarz H, Esplen MJ, Hack T, Hamel M, Howes J, et al. Howell D, Keshavarz H, Esplen MJ, Hack T, Hamel M, Howes J, et al. Radiation therapy side effects: integrating a survivorship clinical lens to better serve patients. J Am Coll Radiol 2019;16(11):1415-25. Epub 2019 Oct 14.

26. Pitman A, Suleman S, Hyde N, Hodgkiss A. Depression and anxiety in patients with cancer. Frontline Gastroenterol 2020;27(6):336-40. Epub 2020 Dec 1.

27. Ingledew PA, Kong T, Jiang W. Screening, assessment and management of psychosocial distress, depression and anxiety in molecular pathology. Clin Oncol (R Coll Radiol) 2014;26(1):10-7. Epub 2013 Aug 29.

28. Pitman A, Suleman S, Hyde N, Hodgkiss A. Depression and anxiety in patients with cancer. BMJ 2018;361:k2145.

29. Ortega J, Kromer E, Collis P, Leitzen C, Mahlmann B, et al. Hydrofilm polyurethane films reduce radiation dermatitis severity in hypofractionated whole-breast irradiation: an objective, intra-patient randomized dual-center assessment. Polymers (Basel) 2019;11(10):2112.

30. Bolderston A, Cashell A, McQuestion M, Cardoso M, Summers C, Harris R. A Canadian survey of the management of radiation-induced skin reactions. J Med Imaging Radiat Sci 2018;49(2):144-72. Epub 2018 Mar 2.

31. Bolderton A, Lloyd NS, Wong RK, Holder L, Robb-Blunderman L; Supportive Care Guidelines Group of Cancer Care Ontario Program in Evidence-Based Care. The prevention and management of acute skin reactions related to radiation therapy: a systematic review and practice guideline. Support Care Cancer 2006;14(6):803-17. Epub 2006 Jun 7.

32. Oral care (mouth care). Toronto, ON: Cancer Care Ontario. Available from: https://www.cancercareontario.ca/en/symptom-management/3796. Accessed 2021 Jul 20.

33. Care of radiation therapy side effects: head and neck. Vancouver, BC: BC Cancer; 2021. Available from: http://www.bccancer.bc.ca/patient-and-public-info-site/Documents/KT%20side%20effects%20education%20Materials/Care-of-Radiation-Therapy-Side-Effects-Head-and-Neck.pdf. Accessed 2021 Jul 20.

34. Chaput G, Ibrahim M, Towers A. Cancer-related lymphedema: clinical pearls for providers. Curr Oncol 2020;27(6):1336-40. Epub 2020 Dec 1.

35. Hanania AN, Mairinwaring W, Ghebre YT, Hanania NA, Ludwig M. Radiation-induced lung injury: assessment and management. Chest 2019;155(3):650-62. Epub 2019 Apr 15.

36. Dilila V, Chaput G, Williams T, Sultanem K. Radiotherapy side effects: integrating a survivorship clinical lens to better serve patients. Curr Oncol 2020;27(3):107-12. Epub 2020 May 1.

37. Carpenter DJ, Mowery YM, Broadwater G, Rodrigues A, Wisdom AJ, Dohr JA, et al. The risk of carotid stenosis in head and neck cancer patients after radiation therapy. Urol Oncol 2018;36(9):69-75. Epub 2018 Mar 14.

38. Guirao L, Nort, De Ruysscher D, Voois MA. Radiation-induced lung injury (RILI). Front Oncol 2019;9:87.

39. Deng G, Liang N, Xie J, Luo H, Qiao Z, Zhang J, et al. Pulmonary toxicity generated from radiotherapy-induced treatment of thoracic malignancies. Oncol Lett 2017;13(4):1501-11. Epub 2017 May 26.

40. Wang H, Wei J, Zheng Q, Meng L, Xin Y, Yin X, et al. Radiation-induced heart disease: a review of classification, mechanism and prevention. Int J Biol Sci 2019;5(10):2128-38.

41. Arminian SH, Laccetti C, Lennihan B. Prevention and monitoring of cardiac dysfunction in survivors of adult cancer. American Society of Clinical Oncology Clinical Practice Guideline Summary. J Pract Oncol 2017;38(5):270-5. Epub 2016 Dec 6.

42. Adams E, Boulton MG, Horne A, Rose PW, Burrell L, Collingwood M, et al. The effects of pelvic radiotherapy on cancer survivors: symptom profile, psychological morbidity and quality of life. Clin Oncol (R Coll Radiol) 2014;26(11):701-7. Epub 2014 Aug 29.

43. Andriyev RH, Muls AC, Norton C, Ralph C, Watson L, Shaw C, et al. Guidance: the practical management of the gastrointestinal symptoms of pelvic radiation disease. Frontline Gastroenterol 2015;6(1):51-7. Epub 2014 Jun 17.

44. Laerma TA, Green J, Bapersfeld M, Wedlake L, Burden S, Davidson SE, et al. Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic cancers. Cochrane Database Syst Rev 2018(13):CD012529.

45. Sex, intimacy and cancer: Toronto, ON: Canadian Cancer Society; 2019. Available from: http://canancer.ca/en/cancer-information/resources/publications/see-intimacy-and-cancer. Accessed 2021 July 19.

46. Berkley F. Managing the adverse effects of radiation therapy. Am Fam Physician 2016;94(3):381-8, 389.

47. Wu Y, Voswathanan AN. Impact of radiotherapy on fertility, pregnancy, and neonatal outcomes in female cancer patients. Int J Radiat Oncol Biol Phys 2009;73(5):1304-12.